FDA Head “Carefully Supports” More Flavored Vape Authorizations
The Acting Director of the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP), Bret Koplow, has signaled a potential shift in the agency’s approach to tobacco control, expressing support for a “tobacco harm reduction” strategy to lower cigarette smoking rates. Speaking at the Food and Drug Law Institute (FDLI) conference, Koplow stated he “carefully supports” the potential for expanding the range of authorized flavored e-cigarettes.
Koplow emphasized the need to establish a “legal marketplace” limited to authorized, lower-risk products, supported by strong enforcement. However, he critically noted that for this harm reduction promise to be effective, the FDA must “dramatically streamline, simplify and accelerate the review and authorization process.” Without a faster and more efficient regulatory pathway, he warned, the unregulated market will continue to thrive, and the agency’s harm reduction commitments “will end up being hollow words.”
Additionally, Koplow announced that the FDA plans to increase public education on the “continuum of risk” among different nicotine products to better inform consumers and healthcare providers. Attendees, including Cliff Douglas, former CEO of the Foundation for a Smoke-Free World, described Koplow’s remarks as a “welcome change in tone.” His clear articulation of the benefits of “switching from cigarettes to pouches and vapes” was seen as a refreshing and potentially groundbreaking statement from the agency’s leadership.
- Argentina: Catamarca Senate Passes Law 5950 to Regulate E-Cigarettes - July 31, 2026
- Malaysia Weighs Vape Ban as Healthcare Costs Outpace Taxes - July 31, 2026
- 4th Circuit Upholds North Carolina Law Banning Unapproved Vapes - July 31, 2026







